Voriconazole Drastically Increases Exposure to Oral Oxycodone

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 2008 Oct 7

PMID 18836708

Citations 31

Authors

Nora M Hagelberg

Tuija H Nieminen

Teijo I Saari

Mikko Neuvonen

Pertti J Neuvonen

Kari Laine

Klaus T Olkkola

Affiliations

Soon will be listed here.

Abstract

Objective: We investigated the effect of voriconazole on the pharmacokinetics and pharmacodynamics of oxycodone.

Methods: Twelve healthy subjects ingested either voriconazole or placebo for 4 days in a randomized, cross-over study. On day 3, they ingested 10 mg oxycodone. Timed plasma samples were collected for the measurement of oxycodone, noroxycodone, oxymorphone, noroxymorphone and voriconazole up to 48 h, and pharmacodynamic effects were recorded.

Results: When voriconazole was taken at the same time as oxycodone, the mean area under the plasma concentration-time curve (AUC(0-infinity)) of oxycodone increased 3.6-fold (range 2.7- to 5.6-fold), peak plasma concentration 1.7-fold and elimination half-life 2.0-fold (p < 0.001) when compared to placebo. The AUC(0-infinity) ratio of noroxycodone to oxycodone was decreased by 92% (p < 0.001), and that of oxymorphone increased by 108% (p < 0.01). Pharmacodynamic effects of oxycodone were modestly increased by voriconazole.

Conclusions: Voriconazole inhibits the CYP3A-mediated N-demethylation of oxycodone, drastically increasing exposure to oral oxycodone. Clinically, lower doses of oxycodone may be needed during voriconazole treatment to avoid opioid-related adverse effects especially after repeated dosing.

Citing Articles

The effect of icotinib or apatinib on the pharmacokinetic profile of oxycodone in rats and the underlying mechanism.

Zhou Q, Ye F, Ye Z, Gao N, Kong Q, Hu X PeerJ. 2023; 11:e16601.

PMID: 38089912 PMC: 10712305. DOI: 10.7717/peerj.16601.

Importance of cytochrome 3A4 and 2D6-mediated drug-drug interactions in oxycodone consumption among older adults hospitalized for hip fracture: a cross-sectional study.

Decaix T, Gautier S, Royer L, Laprevote O, Tritz T, Siguret V Aging Clin Exp Res. 2023; 35(11):2471-2481.

PMID: 37861957 DOI: 10.1007/s40520-023-02569-7.

Hydrocodone, Oxycodone, and Morphine Metabolism and Drug-Drug Interactions.

Coates S, Lazarus P J Pharmacol Exp Ther. 2023; 387(2):150-169.

PMID: 37679047 PMC: 10586512. DOI: 10.1124/jpet.123.001651.

Enzalutamide Reduces Oxycodone Exposure in Men with Prostate Cancer.

Detert Oude Weme S, Hulskotte L, Vervenne W, Imholz A, Cremers R, Taxis K Clin Pharmacokinet. 2023; 62(7):989-996.

PMID: 37162620 PMC: 10338391. DOI: 10.1007/s40262-023-01255-1.

The Overview on the Pharmacokinetic and Pharmacodynamic Interactions of Triazoles.

Czyrski A, Resztak M, Swiderski P, Brylak J, Glowka F Pharmaceutics. 2021; 13(11).

PMID: 34834376 PMC: 8620887. DOI: 10.3390/pharmaceutics13111961.

References

Michna E, Ross E, Hynes W, Nedeljkovic S, Soumekh S, Janfaza D . Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. J Pain Symptom Manage. 2004; 28(3):250-8. DOI: 10.1016/j.jpainsymman.2004.04.007. View

Neuvonen M, Neuvonen P . Determination of oxycodone, noroxycodone, oxymorphone, and noroxymorphone in human plasma by liquid chromatography-electrospray-tandem mass spectrometry. Ther Drug Monit. 2008; 30(3):333-40. DOI: 10.1097/FTD.0b013e31816e2d4b. View

Pennick G, Clark M, Sutton D, Rinaldi M . Development and validation of a high-performance liquid chromatography assay for voriconazole. Antimicrob Agents Chemother. 2003; 47(7):2348-50. PMC: 161850. DOI: 10.1128/AAC.47.7.2348-2350.2003. View

. Measurement of recovery from outpatient general anaesthesia with a simple ocular test. Br Med J. 1970; 3(5715):132-5. PMC: 1702242. DOI: 10.1136/bmj.3.5715.132. View

Olkkola K, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg J . A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther. 1993; 53(3):298-305. DOI: 10.1038/clpt.1993.25. View

Sarton E, Olofsen E, Romberg R, den Hartigh J, Kest B, Nieuwenhuijs D . Sex differences in morphine analgesia: an experimental study in healthy volunteers. Anesthesiology. 2000; 93(5):1245-54; discussion 6A. DOI: 10.1097/00000542-200011000-00018. View

Olkkola K, Ahonen J, Neuvonen P . The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg. 1996; 82(3):511-6. DOI: 10.1097/00000539-199603000-00015. View

Curry S, Watts D, Katz K, Bikin D, Bukaveckas B . The effect of single-dose tramadol on oxycodone clearance. J Emerg Med. 2007; 33(4):407-11. DOI: 10.1016/j.jemermed.2007.03.042. View

Heiskanen T, Olkkola K, Kalso E . Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther. 1999; 64(6):603-11. DOI: 10.1016/S0009-9236(98)90051-0. View

10.

Susce M, Murray-Carmichael E, De Leon J . Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 30(7):1356-8. DOI: 10.1016/j.pnpbp.2006.03.018. View

11.

Ahonen J, Olkkola K, Neuvonen P . Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Eur J Clin Pharmacol. 1997; 51(5):415-9. DOI: 10.1007/s002280050223. View

12.

Thompson S, Koszdin K, Bernards C . Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology. 2000; 92(5):1392-9. DOI: 10.1097/00000542-200005000-00030. View

13.

Saari T, Laine K, Leino K, Valtonen M, Neuvonen P, Olkkola K . Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life. Clin Pharmacol Ther. 2006; 80(5):502-8. DOI: 10.1016/j.clpt.2006.07.008. View

14.

Saari T, Laine K, Leino K, Valtonen M, Neuvonen P, Olkkola K . Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects. Br J Clin Pharmacol. 2006; 63(1):116-20. PMC: 2000716. DOI: 10.1111/j.1365-2125.2006.02707.x. View

15.

Eap C, Broly F, Mino A, Hammig R, Deglon J, Uehlinger C . Cytochrome P450 2D6 genotype and methadone steady-state concentrations. J Clin Psychopharmacol. 2001; 21(2):229-34. DOI: 10.1097/00004714-200104000-00016. View

16.

Poyhia R, Seppala T, Olkkola K, Kalso E . The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol. 1992; 33(6):617-21. PMC: 1381353. DOI: 10.1111/j.1365-2125.1992.tb04090.x. View

17.

Niwa T, Inoue-Yamamoto S, Shiraga T, Takagi A . Effect of antifungal drugs on cytochrome P450 (CYP) 1A2, CYP2D6, and CYP2E1 activities in human liver microsomes. Biol Pharm Bull. 2005; 28(9):1813-6. DOI: 10.1248/bpb.28.1813. View

18.

Sistonen J, Fuselli S, Levo A, Sajantila A . CYP2D6 genotyping by a multiplex primer extension reaction. Clin Chem. 2005; 51(7):1291-5. DOI: 10.1373/clinchem.2004.046466. View

19.

Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen L, Shen D . Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther. 2006; 79(5):461-79. DOI: 10.1016/j.clpt.2006.01.009. View

20.

De Leon J, Dinsmore L, Wedlund P . Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers. J Clin Psychopharmacol. 2003; 23(4):420-1. DOI: 10.1097/01.jcp.0000085421.74359.60. View